{"disease":{"id":"retinal-vein-occlusion-with-macular-edema","name":"retinal vein occlusion with macular edema"},"drugs":{"marketed":[{"drug_id":"aflibercept","indication_name":"Branch retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vegf Trap","generic_name":"AFLIBERCEPT","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor","quality_score":55,"revenue":"9800","mechanism":""},{"drug_id":"aflibercept","indication_name":"Central retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vegf Trap","generic_name":"AFLIBERCEPT","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor","quality_score":55,"revenue":"9800","mechanism":""},{"drug_id":"eylea","indication_name":"Branch retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Eylea","company_name":"Texas Retina Associates","drug_phase":"marketed","molecular_target":"Placenta growth factor, Vascular endothelial growth factor A, Vascular endothelial growth factor B","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"eylea","indication_name":"Central retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Eylea","company_name":"Texas Retina Associates","drug_phase":"marketed","molecular_target":"Placenta growth factor, Vascular endothelial growth factor A, Vascular endothelial growth factor B","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"lucentis","indication_name":"Branch retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lucentis","company_name":"Santen Inc.","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"lucentis","indication_name":"Central retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lucentis","company_name":"Santen Inc.","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"ranibizumab-nuna","indication_name":"Branch retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BYOOVIZ","generic_name":"RANIBIZUMAB-NUNA","company_name":"SAMSUNG BIOEPIS CO LTD","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Branch retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"ranibizumab-nuna","indication_name":"Central retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BYOOVIZ","generic_name":"RANIBIZUMAB-NUNA","company_name":"SAMSUNG BIOEPIS CO LTD","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Central retinal vein occlusion with macular edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":10,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04455399","title":"Time Efficiency Comparison of Two IntraVitreal Injection Techniques","phase":"NA","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Peregrine Eye and Laser Institute","has_results":false},{"nct_id":"NCT05832996","title":"Cool vs Room-temperature Artificial Tears","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":124,"lead_sponsor_name":"University of Iowa","has_results":true},{"nct_id":"NCT04444492","title":"Combination of Ranibizumab and Targeted Laser Photocoagulation","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"University of Giessen","has_results":false},{"nct_id":"NCT03709745","title":"Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":110,"lead_sponsor_name":"St. Erik Eye Hospital","has_results":false},{"nct_id":"NCT04576689","title":"Safety and Efficacy of IBE-814 Intravitreal (IVT) Implant - a Sustained, Low Dose Dexamethasone Therapy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Ripple Therapeutics Pty Ltd","has_results":false},{"nct_id":"NCT04290195","title":"Use of Ziv Aflibercept in Different Retinal Diseases","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"Amin El Sayed Nawar","has_results":false},{"nct_id":"NCT03405376","title":"Prospective Trial of Treat and Extend Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":49,"lead_sponsor_name":"Yeungnam University College of Medicine","has_results":false},{"nct_id":"NCT05282420","title":"Ranibizumab Versus Aflibercept for CRVO in Young Patients.","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"South Valley University","has_results":false},{"nct_id":"NCT03892434","title":"Bevacizumab Versus DEX Implant Followed by Bevacizumab in ME Secondary to BRVO","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Yeungnam University College of Medicine","has_results":false},{"nct_id":"NCT06708624","title":"Ocular Safety and Usability Study for FYB201 PFS","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Formycon AG","has_results":false},{"nct_id":"NCT04812977","title":"Comparison of Intravitreal Anti-VEGF Versus Combination Therapy in Central Retinal Vein Occlusion","phase":"NA","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Hayatabad Medical Complex","has_results":true},{"nct_id":"NCT06708637","title":"Ocular Safety and Usability Study for FYB203 PFS","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Formycon AG","has_results":false}],"total":12},"guidelines":[],"source":"Drug Landscape verified database"}